UDP-Galactose-4-Epimerase (GALE) Peptid
GALE
Reaktivität: Human
Wirt: Synthetic
BP, WB
Produktnummer ABIN977242
150,78 €
Zzgl. Versandkosten 20,00 € und MwSt
100 μg
Lieferung nach:
Deutschland
Lieferung in 15 bis 22 Werktagen
Kurzübersicht für UDP-Galactose-4-Epimerase (GALE) Peptid (ABIN977242)
Target
GALE
(UDP-Galactose-4-Epimerase (GALE))
Spezies
Human
Quelle
Synthetic
Applikation
Blocking Peptide (BP), Western Blotting (WB)
-
-
Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti-GALE antibody (Catalog #: ARP54393_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Aufreinigung
- Purified
-
-
-
-
Applikationshinweise
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Konzentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Handhabung
- Avoid repeated freeze-thaw cycles.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- GALE (UDP-Galactose-4-Epimerase (GALE))
-
Hintergrund
-
GALE is an UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only on exogenous galactose, but also on exogenous N-acetylgalactosamine as a necessary precursor for the synthesis of glycoproteins and glycolipids. Mutations in this gene result in epimerase-deficiency galactosemia, also referred to as galactosemia type 3, a disease characterized by liver damage, early-onset cataracts, deafness and mental retardation, with symptoms ranging from mild ('peripheral' form) to severe ('generalized' form). This gene encodes UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only on exogenous galactose, but also on exogenous N-acetylgalactosamine as a necessary precursor for the synthesis of glycoproteins and glycolipids. Mutations in this gene result in epimerase-deficiency galactosemia, also referred to as galactosemia type 3, a disease characterized by liver damage, early-onset cataracts, deafness and mental retardation, with symptoms ranging from mild ('peripheral' form) to severe ('generalized' form). Multiple alternatively spliced transcripts encoding the same protein have been identified.
Alias Symbols: SDR1E1
Protein Interaction Partner: GALE,GALE
Protein Size: 348 -
Molekulargewicht
- 38 kDa
-
Gen-ID
- 2582
-
NCBI Accession
- NM_001008216, NP_001008217
-
UniProt
- Q14376
Target
-
Sie sind hier:
